ZM 240401
Alternative Names: Fluoroshikimic acidLatest Information Update: 08 Feb 2008
At a glance
- Originator AstraZeneca
- Class Antibacterials
- Mechanism of Action Aromatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 26 Oct 1995 No Development Reported - Preclinical for Bacterial infections in United Kingdom (unspecified route)